[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Nixon BK, Kussick SJ, Carlon MJ, Rubin BP: Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm. Mod Pathol; 2005 Aug;18(8):1121-6
MedlinePlus Health Information. consumer health - Birthmarks.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma involving hemangiomas: an unusual presentation of a rare neoplasm.
  • Both patients were women, 64 and 55 years of age, who presented with long-standing cutaneous hemangiomas of the posterior scalp and left shoulder, respectively.
  • Treatment consisted of chemotherapy (both patients) and adjuvant radiation therapy (one patient).
  • Although this is a rare neoplasm, it is important to consider intravascular large B-cell lymphoma in the differential diagnosis of vascular lesions containing intravascular neoplastic cells.
  • [MeSH-minor] Antigens, CD19 / analysis. Antigens, CD20 / analysis. Antigens, CD45 / analysis. Antigens, CD5 / analysis. DNA-Binding Proteins / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Interferon Regulatory Factors. Middle Aged. Neoplasm Recurrence, Local. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803190.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Antigens, CD5; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / interferon regulatory factor-4; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


2. Mowry SE, Tang C, Sadeghi A, Wang MB: Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients. Eur Arch Otorhinolaryngol; 2010 Jul;267(7):1111-6
eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study are to identify differences in quality of life (QOL) between patients with advanced oropharyngeal cancer following traditional chemoradiation versus chemotherapy with intensity-modulated radiation therapy (CIMRT).
  • Fifty patients were identified from an institutional database of patients who had undergone primary chemotherapy and radiation (traditional or IMRT) for advanced oropharyngeal carcinoma.
  • The patients completed the survey between 9 and 44 months following end of treatment.
  • When adjusted for tumor stage and time since treatment, CIMRT patients reported improved appearance (p = 0.05), chewing (p = 0.02), and mood (p = 0.01).
  • There were no differences between the two groups for saliva, taste, shoulder function, speech, and swallowing.
  • Patients undergoing CIMRT also report slightly better QOL overall when compared to patients receiving more traditional forms of radiation therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Quality of Life
  • [MeSH-minor] Chi-Square Distribution. Humans. Male. Neoplasm Staging. Radiotherapy, Intensity-Modulated. Statistics, Nonparametric. Surveys and Questionnaires. Treatment Outcome

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3964-71 [12351593.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):742-51 [12377326.001]
  • [Cites] Acta Otolaryngol. 2003 Jan;123(1):5-7 [12625565.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):61-70 [12909216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):161-6 [14697434.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Apr;130(4):401-8 [15096421.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):725-31 [16199308.001]
  • [Cites] Laryngoscope. 2006 Sep;116(9):1589-93 [16954985.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Jun;265(6):627-37 [18392633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):966-74 [17145527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):975-80 [16965864.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):651-9 [17175118.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1354-60 [17689885.001]
  • [Cites] Radiother Oncol. 2007 Oct;85(1):64-73 [17714815.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2007 Jun;264(6):651-7 [17273840.001]
  • (PMID = 20039175.001).
  • [ISSN] 1434-4726
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2874032
  •  go-up   go-down


3. Gupta GR, Yasko AW, Lewis VO, Cannon CP, Raymond AK, Patel S, Lin PP: Risk of local recurrence after deltoid-sparing resection for osteosarcoma of the proximal humerus. Cancer; 2009 Aug 15;115(16):3767-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The anatomy of the shoulder poses special challenges with regard to limb-sparing surgery.
  • However, this can compromise the functional results after reconstruction of the shoulder.
  • All patients received neoadjuvant chemotherapy followed by surgery and postoperative chemotherapy.
  • At the time of last follow-up, 14 (61%) of 23 of patients were alive without evidence of disease.
  • Three (13%) patients developed local recurrence.
  • Two of these patients had poor responses to chemotherapy, with tumor necrosis of 50% and 70%.
  • Positive surgical margins were associated with local recurrence, and 2 of 4 patients with a positive surgical margin developed local recurrence (P = .01).
  • Routine use of the procedure is not justified, because it may be associated with an elevated risk of recurrence.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Female. Humans. Male. Muscles / blood supply. Muscles / surgery. Neoplasm Recurrence, Local. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517468.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Strzelczyk A, Vogt H, Hamer HM, Krämer G: Continuous phenobarbital treatment leads to recurrent plantar fibromatosis. Epilepsia; 2008 Nov;49(11):1965-8
Hazardous Substances Data Bank. Phenobarbital .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous phenobarbital treatment leads to recurrent plantar fibromatosis.
  • Although associated connective tissue disorders were described in a timely way after its introduction, the association between plantar fibromatosis--also called Ledderhose syndrome--and phenobarbital seems not to be well known in general.
  • Our case series uniquely demonstrates that continuous phenobarbital treatment leads to recurrent plantar fibromatosis and may result in long-term disability and numerous unnecessary operations.
  • In general, the association between connective tissue disorders and phenobarbital most prominently appears in adult patients of northern European descent.
  • However, our case series and data from the literature suggest that patient groups less susceptible to connective tissue disorders may as well develop Ledderhose syndrome or other associated syndromes as Dupuytren's contractures, frozen shoulder, Peyronie's disease or complex regional pain syndrome in the course of phenobarbital treatment.
  • [MeSH-major] Anticonvulsants / adverse effects. Epilepsy / drug therapy. Fibroma / chemically induced. Fibroma / pathology. Foot Diseases / chemically induced. Foot Diseases / pathology. Neoplasms, Connective Tissue / chemically induced. Neoplasms, Connective Tissue / pathology. Phenobarbital / adverse effects
  • [MeSH-minor] Adult. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Primidone / therapeutic use

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • Hazardous Substances Data Bank. PRIMIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513351.001).
  • [ISSN] 1528-1167
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 13AFD7670Q / Primidone; YQE403BP4D / Phenobarbital
  •  go-up   go-down


5. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM: Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev; 2007 Apr;33(2):101-37
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
  • BACKGROUND: We hypothesized excess resistance factor ("active resistance") gives a dose--response curve (DRC) shoulder, deficiency of a factor required for drug sensitivity ("saturable passive resistance") gives a DRC terminal plateau, and alteration of a factor gives decreased DRC slope.
  • Patient median survival times also failed to vary significantly with dose for any combination.
  • CONCLUSIONS: DRC flattening at higher doses suggests therapy efficacy is limited by deficiency/saturation of factors required for cell killing.
  • (1) active resistance may modulate cell killing at lower doses, but ability to overcome this by increasing doses is limited by saturable passive resistance (e.g. by non-cycling cells). (2) Cells surviving initial chemotherapy may upregulate active resistance mechanisms (permitting growth despite therapy). (3) If active resistance mechanisms are insufficient for growth/survival, cells may survive until therapy cessation by downregulating metabolism/cycling, becoming temporarily quiescent.
  • This could help explain broad cross-resistance between agents and would imply that improved targeting of non-cycling cells will be required for major improvement in therapy efficacy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Resistance, Neoplasm. Lung Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Humans. Paclitaxel / administration & dosage. Survival Rate. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17276603.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 595
  •  go-up   go-down


6. Shi SF, Dong Y, Zhang CL, Bao K, Ma XJ: [Prosthesis replacement of the proximal humerus after the resection of bone tumors]. Chin J Cancer; 2010 Jan;29(1):121-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: After chemotherapy was used to treat patients with malignant bone tumors in 1970s, amputation, which was the typical intervention in the 1980s, has been substituted with limb-sparing surgery.
  • Local recurrence presented in 1 patient with GCT, 1 patient had inner infection in the area of surgery, and 2 patients had shoulder subluxation after the operation.
  • The abduction angle of the shoulder was 8 degrees-35 degrees, and circumgyrate angle was 18 degrees-25 degrees, with flexion 35 degrees-90 degrees and extension 25 degrees-42 degrees.
  • According to the functional score developed by the International Society of Limb Salvage, scores ranged between 18 and 29 points, with an average of 24 points.
  • CONCLUSIONS: The prosthesis replacement for the patients with bone tumors in the proximal humerus is an appropriate procedure with satisfactory therapeutic outcomes; however, many complications should be noted and long-term therapeutic effect needs further investigations.
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement. Female. Follow-Up Studies. Giant Cell Tumor of Bone / pathology. Giant Cell Tumor of Bone / radiography. Giant Cell Tumor of Bone / surgery. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Range of Motion, Articular. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Oguri T, Achiwa H, Kato D, Maeda H, Niimi T, Sato S, Ueda R: Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy; 2004 Dec;50(6):279-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma.
  • Thymic carcinoma is a rare and aggressive tumor, and the efficacy of second-line chemotherapy is still unclear.
  • Here, we reported a case of thymic carcinoma that responded well to the administration of docetaxel alone as a second-line chemotherapy.
  • A 64-year-old woman was diagnosed with thymic carcinoma (squamous cell type) with bone metastasis, and she, therefore, received nedaplatin combined with etoposide and ifosfamide.
  • Two months after chemotherapy, the thymic carcinoma exhibited gradual regrowth and she experienced shoulder pain.
  • After three courses of docetaxel, we observed a partial response and her shoulder pain disappeared.
  • This case demonstrated that docetaxel is effective as a second-line chemotherapy for thymic carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cervical Vertebrae / pathology. Mediastinal Neoplasms / drug therapy. Salvage Therapy / methods. Spinal Neoplasms / drug therapy. Taxoids / therapeutic use. Thymoma / drug therapy. Thymus Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Female. Humans. Mediastinum / radiography. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15608443.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


8. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • CONCLUSION: Surgical treatment should be considered in patients with pancreatic metastasis from other organs if the disease is localized in the pancreas or if metastasis in other organs is controlled with chemotherapy and/or radiotherapy.
  • [MeSH-minor] Back Pain / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Shoulder Pain / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Friedrichs B, Thiel E: [Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous stem cell transplantation]. Dtsch Med Wochenschr; 2010 Sep;135(38):1857-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous stem cell transplantation].
  • [Transliterated title] Pulmonale lymphomatoide Granulomatose Grad III: kurativer Therapieansatz mit Radioimmuntherapie und autologer Stammzelltransplantation.
  • She had been treated for persistent shoulder pain for several months.
  • INVESTIGATIONS: A chest X-ray and subsequent computed tomography (CT) scans showed a lesion measuring 10×8 cm in the right upper pulmonary lobe.
  • TREATMENT AND COURSE: After 6 cycles of rituximab, cyclophosphamide, doxorubicin, vincristin and prednisolone (R-CHOP), an early relapse developed which was treated with rituximab, ifosphamid, methotrexate and etoposide.
  • Good partial remission was achieved after consolidating high-dose chemotherapy followed by autologous stem cell transplantation (ASCT).
  • After two years of rituximab maintenance treatment positron emission tomography (PET-CT) revealed an increase of metabolic activity.
  • A second high-dose therapy was then combined with Y-90 ibritumomab tiuxetan, which was well tolerated.
  • CONCLUSIONS: Combination of Y-90 ibritumomab tiuxetan and high-dose chemotherapy followed by ASCT may offer an efficacious and well-tolerated targeted treatment approach for patients with relapsed lymphomatoid granulomatosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lung Neoplasms / therapy. Lymphomatoid Granulomatosis / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Image Processing, Computer-Assisted. Infant. Lung / pathology. Pneumonectomy. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphomatoid granulomatosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 20842604.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / ibritumomab tiuxetan
  •  go-up   go-down


10. Chughtai A, Cronin P, Lucas DR, Prager R, Kazerooni EA: Metastatic shoulder liposarcoma to the right ventricle: CT findings. J Thorac Imaging; 2007 May;22(2):195-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic shoulder liposarcoma to the right ventricle: CT findings.
  • A right ventricular liposarcoma metastasis is described in a 46-year-old man, who was admitted with significant shortness of breath and fatigue, and in whom a large lobulated low attenuation mass occupying most of the right ventricular cavity, with extension through the right ventricular apex and a small-to-moderate pericardial effusion was detected by electrocardiogram-gated cardiac computed tomography.
  • The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier.
  • Surgical resection was performed with the majority of the neoplasm removed though; the right ventricular apex and epicardial extension of tumor could not be fully resected.
  • Electrocardiogram-gated cardiac computed tomography was able to visualize the metastatic tumor within the heart, accurately evaluate cardiac function and allow for prompt surgical treatment that produced relief of symptoms, and assess for further metastatic disease within the thorax.
  • [MeSH-major] Bone Neoplasms / pathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Liposarcoma / diagnosis. Shoulder / pathology. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527130.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


11. Rodriguez Martin J, Pretell Mazzini J, Viña Fernandez R, Marti Ciruelos R, Curto de la Mano A: Ewing sarcoma of clavicle in children: report of 5 cases. J Pediatr Hematol Oncol; 2009 Nov;31(11):820-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean age at the time of diagnosis was 11.6 years (2 to 15 y).
  • All patients received chemotherapy before and after the surgery.
  • Different methods of surgical treatment were used and included: claviculectomy, claviculectomy and vascularized fibular autograft, and claviculectomy and clavicle allograft.
  • The remaining 4 patients had good functional outcomes with no pain of the shoulder at final follow-up.
  • In conclusion, Ewing sarcoma of clavicle is a very rare tumor and different methods of surgical treatment can be used.
  • Autografts or allografts can restore the normal anatomy of the shoulder.
  • [MeSH-major] Bone Neoplasms / therapy. Clavicle. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Remission Induction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801950.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Rifkin S, Valderrama E, Lipton JM, Karayalcin G: Lymphomatoid papulosis and Ki-1+ anaplastic large cell lymphoma occurring concurrently in a pediatric patient. J Pediatr Hematol Oncol; 2001 Jun-Jul;23(5):321-3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomatoid papulosis (LyP) is a benign, self-healing, papular eruption that can wax and wane over the course of time.
  • After treatment with chemotherapy, she has been in continuous remission for 16 months.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Clone Cells / chemistry. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Neoplasm Invasiveness. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Prednisone / administration & dosage. Remission Induction. Shoulder. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11464993.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


13. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • The patient received adjuvant chemotherapy (ifosfamide/mesna, adriamycin, and dacarbazine/MAID) and finally radiation therapy (RT; 6500 cGy total dose).
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


14. Thomison J, McCarter M, McClain D, Golitz LE, Goldenberg G: Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol; 2008 Nov;35(11):1003-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
  • We report a novel histological finding in a dermatofibrosarcoma protuberans (DFSP) after treatment with imatinib mesylate: copious amounts of hyalinized collagen.
  • A 57-year-old female was referred for evaluation and treatment of a 7 x 8 x 10 cm tumor on the right anterior shoulder.
  • Histological evaluation of the incisional biopsy showed a highly cellular dermal neoplasm composed of spindle cells arranged in a storiform pattern with minimal collagen.
  • At the end of therapy, the DFSP decreased in size to 5.5 x 4 x 4 cm.
  • Histological evaluation showed a residual dermal neoplasm composed of atypical spindle cells and a copious amount of hyalinized collagen.
  • A similar finding has been reported in gastrointestinal stromal tumor, which shows deposition of myxohyaline stroma after treatment with imatinib mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Collagen / metabolism. Dermatofibrosarcoma / drug therapy. Hyalin / metabolism. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antigens, CD34 / metabolism. Benzamides. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544062.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; 9007-34-5 / Collagen
  •  go-up   go-down


15. Noriyuki T, Shimatani K, Shintaku S, Uchida T, Asahara T, Nishi T, Nishimura S, Nishino R, Okamoto N, Sanefuji H: [Local advanced lung cancer invaded thoracic vertebral bodies with unruptured cerebral aneurysm]. Kyobu Geka; 2003 Mar;56(3):183-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 57-year-old man presented with the chief complaint of left shoulder pain in June 2001, and paridrosis of left upper trunk and left upper limb in July 2001.
  • Head magnetic resonance imaging (MRI) showed 8 mm sized unrupture aneurysm of left middle cerebral artery, and chest computed tomography (CT) showed the lung tumor invaded thoracic vertebral bodies.
  • The prevented clipping of unrupture aneurysm was performed at 11th September 2001, and left upper lobectomy, hemivertebrectomy and reconstruction of thoracic vertebral body (Th 3-5) with Modul' ICS at 12th October 2001.
  • After the radiotherapy (50 Gy), chemotherapy (gemcitabine and vinorelbine) was performed.
  • But the radiation pneumonia was occurred and chemotherapy was intermitted.
  • The prevented clipping of unrupture cerebral aneurysm and the reconstruction of thoracic vertebral body (Th 3-5) with Modul' ICS were useful for the radical operation of the local advanced lung cancer.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness. Thoracic Surgical Procedures / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Brain Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649907.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. González-Cámpora R, Escudero AG, Ríos Martín JJ, Armas Padrón JR, Vázquez AH, Vázquez Ramírez FJ: Myofibrosarcoma (low-grade myofibroblastic sarcoma) with intracytoplasmic hyaline (fibroma-like) inclusion bodies. Ultrastruct Pathol; 2003 Jan-Feb;27(1):7-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myofibrosarcoma is a controversial neoplasm composed of cells with differentiation toward myofibroblasts.
  • A 66-year-old man complained of a painless enlarged mass in his right shoulder over the previous 6 months.
  • [MeSH-major] Cytoplasm / ultrastructure. Fibrosarcoma / pathology. Hyalin / ultrastructure. Inclusion Bodies / ultrastructure. Myosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Microscopy, Electron. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Shoulder

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554531.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Qayyum A, MacVicar AD, Padhani AR, Revell P, Husband JE: Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. Radiology; 2000 Mar;214(3):837-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques.
  • PURPOSE: To investigate the clinical utility and diagnostic accuracy of magnetic resonance (MR) imaging in patients with symptomatic brachial plexopathy following treatment for breast cancer.
  • MATERIALS AND METHODS: Fifty patients with symptoms of brachial plexopathy (principally pain, weakness, and paresthesia) who had received treatment for breast cancer, which included surgery, radiation therapy, and cytotoxic chemotherapy, underwent MR imaging at 1.5 T.
  • MR imaging was performed by using a body coil, which was supplemented with surface-coil imaging of the cervical spine and shoulder-coil imaging of the brachial plexus.
  • The MR criteria used for detection of tumor yielded a sensitivity of 96%, specificity of 95%, positive predictive value of 96%, and negative predictive value of 95%.
  • CONCLUSION: MR imaging is reliable and accurate in the diagnosis of symptomatic brachial plexopathy following breast cancer therapy.
  • [MeSH-major] Brachial Plexus Neuropathies / diagnosis. Breast Neoplasms / therapy. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachial Plexus / pathology. Combined Modality Therapy. Female. Humans. Image Enhancement. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Sensitivity and Specificity


18. Owens CL, Basaria S, Nicol TL: Metastatic breast carcinoma involving the thyroid gland diagnosed by fine-needle aspiration: a case report. Diagn Cytopathol; 2005 Aug;33(2):110-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction of metastatic carcinoma (MC) or sarcoma from a primary thyroid malignancy is important because the treatment is different.
  • She had undergone mastectomy with subsequent chemotherapy and radiation for infiltrating mammary carcinoma.
  • Subsequent work-up revealed two distinct nodules in the left lobe of her thyroid gland as well as a subcutaneous mass in her right shoulder.
  • Subsequent FNA and biopsy of her right shoulder lesion also revealed metastatic breast carcinoma with similar morphology to the material in the thyroid FNA.
  • [MeSH-minor] Biopsy, Fine-Needle. Breast Neoplasms / complications. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Female. Humans. Middle Aged. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007653.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Arnold PM, Habib A, Newell K, Anderson KK: Esthesioneuroblastoma metastatic to the thoracic intradural and extradural space. Spine J; 2009 May;9(5):e1-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A 64-year-old man with recurrent ENB presented with chronic pain in the neck, shoulder, and back.
  • Computed tomography of the chest showed no pulmonary metastasis and a high-attenuation spinal canal mass at T8 was noted on magnetic resonance imaging.
  • RESULTS: The postoperative period was uneventful, and included pain management and physical therapy, followed by chemotherapy and radiation.
  • [MeSH-minor] Dura Mater / pathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18805062.001).
  • [ISSN] 1878-1632
  • [Journal-full-title] The spine journal : official journal of the North American Spine Society
  • [ISO-abbreviation] Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Takagi Y, Nakamura H, Miwa K, Adachi Y, Fujioka S, Haruki T, Taniguchi Y: A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy. Thorac Cardiovasc Surg; 2010 Aug;58(5):304-6
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of G-CSF-producing invasive apical cancer resected following preoperative adjuvant therapy.
  • The patient was a 47-year-old male with the chief complaints of right shoulder pain and fever.
  • For the brain metastasis, gamma knife treatment and chemotherapy were performed after surgery, and there was no recurrence during 16 months after surgery.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Granulocyte Colony-Stimulating Factor / blood. Lung Neoplasms / therapy. Lymph Node Excision. Pneumonectomy
  • [MeSH-minor] Biopsy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neurosurgical Procedures. Positron-Emission Tomography. Radiotherapy, Adjuvant. Thoracic Wall / pathology. Thoracic Wall / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20680910.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


21. Wollina U, Schönlebe J, Koch A, Haroske G: Atypical fibroxanthoma: a series of 25 cases. J Eur Acad Dermatol Venereol; 2010 Aug;24(8):943-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on co-morbidities, treatment and outcome were obtained.
  • All tumours were localized in the head and neck region, except a single tumour on the shoulder.
  • Medical history was positive for radiotherapy or chemotherapy in four patients.
  • CONCLUSIONS: Micrographic controlled surgery with wide 2 cm safety margins is the treatment of choice.
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cheek. Female. Follow-Up Studies. Forehead. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Retrospective Studies. Scalp. Treatment Outcome. Vimentin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158588.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vimentin
  •  go-up   go-down


22. Bosch-Barrera J, Urdiroz J, Centeno C: [Visual hallucinations and unusual pain related to hypomagnesemia in an advanced cancer patient]. An Sist Sanit Navar; 2010 Sep-Dec;33(3):319-22
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of an advanced cancer patient who had received successive lines of chemotherapy and who was receiving opioid treatment for cancer pain.
  • During his hospital stay, he experienced visual hallucinations and very intense, unexplained pain in one shoulder.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Humans. Hypercalciuria / complications. Lung Neoplasms / complications. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging. Nephrocalcinosis / complications. Renal Tubular Transport, Inborn Errors / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21233868.001).
  • [ISSN] 1137-6627
  • [Journal-full-title] Anales del sistema sanitario de Navarra
  • [ISO-abbreviation] An Sist Sanit Navar
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] Hypomagnesemia primary
  •  go-up   go-down


23. Mankin HJ, Hornicek FJ, Springfield DS: Extra-abdominal desmoid tumors: a report of 234 cases. J Surg Oncol; 2010 Oct 1;102(5):380-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumors arose adjacent to muscles or bones and the largest number were in the foot, shoulder thigh and calf.
  • Thirty-seven had additional radiation and eight had chemotherapy.
  • Of great concern were 24 patients who developed multiple sites metachronously, which required further surgery and in many cases caused disability.
  • [MeSH-major] Fibromatosis, Abdominal / surgery. Fibromatosis, Aggressive / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / statistics & numerical data. Child. Combined Modality Therapy. Disabled Persons / statistics & numerical data. Female. Humans. Male. Middle Aged. Reoperation. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. Surg. Oncol. 2010;102:380-384. © 2009 Wiley-Liss, Inc.
  • (PMID = 19877160.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Verbeek HH, de Groot JW, Plukker JT, Hofstra RW, Brouwers AH, Kerstens MN, Links TP: [Medullary thyroid cancer, a tumour with many appearances]. Ned Tijdschr Geneeskd; 2010;154:A1818
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The second patient, a 64-year-old woman suffering from a painful nodule in the neck and a painful shoulder, was diagnosed with MTC and liver, lung and bone metastases.
  • Current diagnostic procedures of MTC may include positron emission tomography with 18F-deoxyglucose (FDG-PET) and 18F-diphenylalanine (DOPA-PET).
  • Tyrosine kinase inhibitors appear to offer potential new therapeutic possibilities.
  • [MeSH-minor] Adult. Aged, 80 and over. Diagnosis, Differential. Enzyme Inhibitors / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Positron-Emission Tomography. Pyrazoles / therapeutic use. Pyrimidines / therapeutic use. Thyroid Nodule / diagnosis. Thyroid Nodule / drug therapy. Thyroid Nodule / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid cancer, medullary.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858319.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; 0 / Enzyme Inhibitors; 0 / Pyrazoles; 0 / Pyrimidines
  •  go-up   go-down


25. Mittal S, Goswami C, Kanoria N, Bhattacharya A: Post-irradiation angiosarcoma of bone. J Cancer Res Ther; 2007 Apr-Jun;3(2):96-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy is extensively used for treatment of malignancies, but angiosarcomas occurring in an irradiated area are uncommon.
  • The patient presented with progressive painful swelling over right shoulder and his X-ray showed erosion of medial cortex with lytic areas at upper end of humerus.
  • He received four cycles of combination chemotherapy with doxorubicin and ifosfamide and currently is free of recurrence after six months follow-up.
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998731.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


26. Chu AC, Tsang SY, Lo EH, Fung KP: Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci; 2001 Dec 21;70(5):591-601
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, when LDL-DOX or DOX was administered to nude mice bearing HepG2 cells implanted on the shoulder, the anti-proliferative effects on the tumor cells of both drugs were similar.
  • Histological analyses indicated that organization of myocardial filaments was disrupted and vacuolization was observed in DOX-treated group when compared with control group whereas LDL-DOX-treatment did not exhibit any damage in the host's heart.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Doxorubicin / administration & dosage. Lipoproteins, LDL / administration & dosage. Neoplasms, Experimental / drug therapy
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Survival / drug effects. Dose-Response Relationship, Drug. Drug Carriers / administration & dosage. Drug Carriers / pharmacokinetics. Female. Heart / drug effects. Humans. Injections, Intravenous. L-Lactate Dehydrogenase / metabolism. Liver / drug effects. Liver / metabolism. Mice. Mice, Inbred BALB C. Mice, Nude. Myocardium / enzymology. Myocardium / pathology. Neoplasm Transplantation. Tumor Cells, Cultured / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11811903.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Lipoproteins, LDL; 80168379AG / Doxorubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


27. Merimsky O, Kollender Y, Inbar M, Lev-Chelouche D, Gutman M, Issakov J, Mazeh D, Shabat S, Bickels J, Meller I: Is forequarter amputation justified for palliation of intractable cancer symptoms? Oncology; 2001;60(1):55-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amputation has been advocated as a palliative procedure for symptomatic locally advanced disease that has already failed to respond to radiation therapy, chemotherapy and limited surgery.
  • METHODS: Twelve patients with advanced malignant tumors involving the shoulder girdle or the proximal humerus underwent forequarter amputation (FQA) for palliative purposes.
  • Survival was measured in months (3-24 months), but ultimately had no meaning since the procedure was palliative.
  • [MeSH-major] Amputation / methods. Arm / surgery. Neoplasm Recurrence, Local / surgery. Palliative Care / methods. Quality of Life. Shoulder / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150909.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Waragai M, Chiba A, Uchibori A, Fukushima T, Anno M, Tanaka K: Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy. J Neurol Neurosurg Psychiatry; 2006 Jan;77(1):111-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight months after initial onset of symptoms, he demonstrated a head drop with muscular atrophy of the upper limbs, shoulder girdle, and posterior neck.
  • The patient was treated with corticosteroids, intravenous immunoglobulin, and antiepileptic medication.
  • The patient improved clinically and symptom progression ceased after initiation of treatment.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Brain / pathology. Encephalitis / diagnosis. Muscular Atrophy, Spinal / diagnosis. Nerve Tissue Proteins / immunology. Paraneoplastic Syndromes, Nervous System / diagnosis. Paraneoplastic Syndromes, Nervous System / immunology
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunoglobulins, Intravenous / therapeutic use. Magnetic Resonance Imaging. Male. Methylprednisolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Spinal Muscular Atrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):222-5 [11160472.001]
  • [Cites] Ann Neurol. 2001 Sep;50(3):339-48 [11558790.001]
  • [Cites] Arch Neurol. 2004 Nov;61(11):1785-9 [15534190.001]
  • [Cites] Brain. 2004 Aug;127(Pt 8):1831-44 [15215214.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1332-5 [12933950.001]
  • (PMID = 16361608.001).
  • [ISSN] 0022-3050
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulins, Intravenous; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins; X4W7ZR7023 / Methylprednisolone
  • [Other-IDs] NLM/ PMC2117426
  •  go-up   go-down


29. Shah S, Har-El G, Rosenfeld RM: Short-term and long-term quality of life after neck dissection. Head Neck; 2001 Nov;23(11):954-61
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Quality of life (QOL) is an important outcome measure in cancer therapy.
  • RESULTS: The following symptoms were the most commonly experienced after surgery: neck tightness (71%), numbness or burning of the ear (57%), and shoulder discomfort (53%).
  • QOL after ND was negatively associated with previous radiation, previous chemotherapy, tumor stage, and more radical neck surgery but was positively associated with time after surgery.
  • Shoulder discomfort and neck tightness had the greatest affect on QOL.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 John Wiley & Sons, Inc. Head Neck 23: 954-961, 2001.
  • (PMID = 11754499.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Siebenrock KA, Hertel R, Ganz R: Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg; 2000;120(1-2):65-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery.
  • Sixteen referred patients were reviewed after excision of an unexpected soft-tissue sarcoma of the extremities.
  • Four patients received adjuvant local radiation, with additional chemotherapy in 2 of them.
  • At an average follow-up of 4.5 years (range 15-149 months), 4 patients (25%) had developed distant metastases with a local recurrence in 3 (19%).
  • Evaluation by adequate imaging techniques, biopsy, and definitive resection and reconstruction should be performed by an oncologically trained orthopaedic surgeon.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Female. Forearm. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Reoperation. Shoulder

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653107.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


31. Balak F, Roelen CA, Koopmans PC, Ten Berge EE, Groothoff JW: Return to work after early-stage breast cancer: a cohort study into the effects of treatment and cancer-related symptoms. J Occup Rehabil; 2008 Sep;18(3):267-72
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Return to work after early-stage breast cancer: a cohort study into the effects of treatment and cancer-related symptoms.
  • INTRODUCTION: Earlier diagnosis and better treatment have increased the survival rates of cancer patients.
  • What is the effect of the type of treatment and cancer-related symptoms on return to work?
  • In these women, return to work was followed for 24 months after diagnosis and linked to the type of treatment and cancer-related symptoms.
  • The duration of absence depended on the type of treatment and was significantly longer in patients who underwent chemotherapy (hazard rate [HR] = 0.31; 95% confidence interval [CI] = 0.12-0.81) or multimodal treatment (HR = 0.24; 95% CI = 0.10-0.54).
  • Women started working about 4 months after the end of therapy irrespective of the type of treatment.
  • At that moment, reaching above shoulder level was impaired in 11 patients (15%) which significantly delayed partial return to work (HR = 0.48; 95% CI = 0.23-0.98) but not full return to work (HR = 0.63; 95% CI = 0.31-1.26).
  • CONCLUSIONS: The time taken to return to work after early-stage breast cancer was principally determined by the type of treatment.
  • [MeSH-major] Breast Neoplasms / therapy. Sick Leave
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Cohort Studies. Combined Modality Therapy / adverse effects. Female. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Qual Life Res. 2007 Aug;16(6):947-60 [17457697.001]
  • [Cites] AAOHN J. 2007 Jul;55(7):290-5 [17665826.001]
  • [Cites] Psychooncology. 2002 Mar-Apr;11(2):124-31 [11921328.001]
  • [Cites] Eur J Surg Oncol. 2006 Mar;32(2):148-52 [16387467.001]
  • [Cites] Breast Cancer Res Treat. 2005 Nov;94(1):1-10 [16172793.001]
  • [Cites] Occup Environ Med. 2003 May;60(5):352-7 [12709521.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1292-301 [15700265.001]
  • [Cites] Nurs Res. 2003 Nov-Dec;52(6):370-9 [14639083.001]
  • [Cites] Health Serv Res. 2002 Oct;37(5):1309-28 [12479498.001]
  • [Cites] Soc Sci Med. 1993 Aug;37(3):295-304 [8356479.001]
  • [Cites] J Occup Med. 1992 Nov;34(11):1084-9 [1432298.001]
  • [Cites] Disabil Rehabil. 2004 Jan 21;26(2):78-84 [14668143.001]
  • [Cites] J Occup Rehabil. 2007 Mar;17 (1):83-92 [17318459.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8305-12 [16219927.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):896-905 [15151946.001]
  • [Cites] Psychooncology. 1999 Nov-Dec;8(6):467-73 [10607979.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2496-503 [17048250.001]
  • [Cites] Surg Oncol. 2006 Nov;15(3):153-65 [17187979.001]
  • [Cites] Psychooncology. 2006 Aug;15(8):739-47 [16374893.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1629-38 [17134366.001]
  • [Cites] Psychooncology. 2004 Mar;13(3):147-60 [15022150.001]
  • [Cites] Cancer Nurs. 2002 Aug;25(4):283-97; quiz 298-9 [12181497.001]
  • [Cites] J Natl Cancer Inst. 2004 Dec 15;96(24):1813-22 [15601637.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Psychooncology. 2007 Sep;16(9):787-95 [17086555.001]
  • [Cites] J Cancer Surviv. 2007 Jun;1(2):129-36 [18648953.001]
  • [Cites] J Occup Rehabil. 2006 Dec;16(4):647-57 [17063404.001]
  • [Cites] CMAJ. 2005 Sep 27;173(7):765-71 [16186583.001]
  • [Cites] J Womens Health (Larchmt). 2007 Nov;16(9):1348-61 [18001192.001]
  • [Cites] Support Care Cancer. 2005 Apr;13(4):255-65 [15798918.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(11):1562-7 [12855263.001]
  • (PMID = 18670868.001).
  • [ISSN] 1053-0487
  • [Journal-full-title] Journal of occupational rehabilitation
  • [ISO-abbreviation] J Occup Rehabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Pitz CC, de la Rivière AB, van Swieten HA, Duurkens VA, Lammers JW, van den Bosch JM: Surgical treatment of Pancoast tumours. Eur J Cardiothorac Surg; 2004 Jul;26(1):202-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Pancoast tumours.
  • Due to its localisation in the apex of the lung with invasion of the lower part of the brachial plexus, first ribs, vertebrae, subclavian vessels or stellate ganglion, a superior sulcus tumour causes characteristic symptoms, like arm or shoulder pain or Horner's syndrome.
  • Shaw and Paulson introduced combined modality treatment and for many years, this combination of radiotherapy and surgery was the treatment of choice with a mean 5-year survival of approximately 30%.
  • Also the addition of other chemotherapy agents or biologic agents such as angiogenesis inhibitors or tyrosine kinase inhibitors gives a new perspective in the treatment of Pancoast tumours.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15201002.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down






Advertisement